EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Anti‐calcitonin gene‐related peptide treatments in women's health: Gaps and clinical evidence in menstrual‐related migraine, pregnancy, lactation, and hormonal contraception: A narrative review

Anti-CGRP-Behandlungen in der Frauengesundheit: Lücken und klinische Evidenz bei menstruationsassoziierter Migräne, Schwangerschaft, Laktation und hormoneller Kontrazeption: Narrative Review

Jelena Pejic iD, Jeya Anandakumar, Lisa A Marks, Rashmi B Halker Singh iD, Jessica Ailani

Headache: The Journal of Head and Face Pain · 2026-11 · 66 (10) · 2230-2239

DOI: 10.1111/head.70195 ↗

Auf einen Blick

Die narrative Review fasst die Evidenz zu Anti-CGRP-Therapien bei Frauen in reproduktiven Gesundheitssituationen zusammen. Für mehrere Bereiche werden nur begrenzte Daten berichtet.

Fragestellung

Welche Evidenz gibt es für Anti-CGRP-Therapien bei menstruationsassoziierter Migräne, in Schwangerschaft und Laktation sowie bei hormoneller Kontrazeption?

Methode

Systematische Suche in MEDLINE und Embase; 2 unabhängige Reviewer; narrative Synthese nach klinischem Bereich.

Ergebnisse

16 Studien erfüllten die Einschlusskriterien. Bei menstruationsassoziierter Migräne reduzierten CGRP-Antikörper die Migränetage; Galcanezumab: −5,1 vs. −3,2 Tage, p < 0,001. Für Schwangerschaft und Laktation sind die Daten begrenzt.

Einschränkungen

Schwangerschaftsdaten nur aus Pharmakovigilanz und Fallberichten; keine Humanlaktationsdaten für CGRP-Antikörper; keine Studien zu hormoneller Kontrazeption.

Schlussfolgerung der Autor:innen

Es bestehen erhebliche Evidenzlücken in allen untersuchten reproduktiven Gesundheitssituationen. Prospektive Studien, Register und weitere Untersuchungen werden für nötig gehalten.

Kernaussagen

  • 16 Studien wurden eingeschlossen.
  • Galcanezumab reduzierte Migränetage: −5,1 vs. −3,2 Tage.
  • Keine Studien zu hormoneller Kontrazeption; Laktationsdaten zu Antikörpern fehlen.

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Übersichtsarbeit in Headache: The Journal of Head and Face Pain, published online on 2026-09-29. Written by Jelena Pejic and 4 co-authors. Institution: Mayo Clinic Alix School of Medicine, Scottsdale, Arizona, USA. Major MEDLINE topics: Migraine Disorders, Lactation, Calcitonin Gene-Related Peptide, Women's Health. 35 references.

Auf einen BlickAbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

This study was conducted to review and synthesize current evidence on anti‐calcitonin gene‐related peptide (CGRP) therapies in women with menstrual‐related migraine, during pregnancy and lactation, and while using hormonal contraception.

Background

Migraine disproportionately affects women, with prevalence peaking during reproductive years when hormonal fluctuations modulate neurovascular and nociceptive pathways, including CGRP signaling, that contribute to migraine susceptibility. Despite the established efficacy of anti‐CGRP therapies—including monoclonal antibodies (erenumab, fremanezumab, galcanezumab, and eptinezumab) and gepants (ubrogepant, rimegepant, atogepant, and zavegepant)—evidence regarding their use across critical reproductive health contexts remains limited.

Methods

A systematic search of MEDLINE and Embase was conducted using MeSH terms and keywords related to migraine, CGRP‐targeted therapies, and reproductive health contexts. Studies were screened independently by two reviewers. Data were extracted using standardized forms and synthesized narratively by clinical domain.

Results

Sixteen studies met inclusion criteria. For menstrual‐related migraine, post hoc analyses and observational studies demonstrate that CGRP monoclonal antibodies reduce migraine frequency both during and outside the perimenstrual window (galcanezumab: −5.1 vs. −3.2 days, p < 0.001), although the perimenstrual period remains a time of relatively higher headache burden despite treatment. Pregnancy data are limited to pharmacovigilance analyses and case reports of unintended exposures, which have not identified specific patterns of maternal, fetal, or neonatal toxicity. Phase 1 pharmacokinetic studies demonstrate minimal gepant transfer into breast milk (relative infant doses, 0.04%–0.19%), well below the 10% safety threshold, although no human lactation data exist for CGRP monoclonal antibodies. No studies specifically evaluated anti‐CGRP therapies in women using hormonal contraceptives.

Conclusion

Substantial evidence gaps exist across all reproductive health contexts examined. Prospective trials in menstrual‐related migraine, pregnancy registries, lactation studies assessing infant outcomes, and research examining interactions with hormonal contraceptives are needed to optimize migraine care for women.

Subjects

MeSH terms (MEDLINE)

Migraine DisordersLactationCalcitonin Gene-Related PeptideWomen's HealthPregnancy ComplicationsCalcitonin Gene-Related Peptide Receptor AntagonistsHumansFemalePregnancyAntibodies, Monoclonal

Author keywords

breastfeeding safetycalcitonin gene‐related peptide monoclonal antibodieshormonal contraceptionmenstrual‐related migrainereproductive health

Substances

Calcitonin Gene-Related PeptideAntibodies, MonoclonalCalcitonin Gene-Related Peptide Receptor Antagonists

Authors and institutions

  • Mayo Clinic Alix School of Medicine, Scottsdale, Arizona, USA.
  • Georgetown University School of Medicine, Washington, DC, USA.
  • Department of Library Services, Mayo Clinic Arizona, Scottsdale, Arizona, USA.
  • Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Department of Neurology, Georgetown University, Washington, DC, USA.

ORCID profiles: Jelena Pejic, Rashmi B Halker Singh

Cite

APA

Pejic, J., Anandakumar, J., Marks, L. A., Halker Singh, R. B., & Ailani, J. (2026). Anti‐calcitonin gene‐related peptide treatments in women's health: Gaps and clinical evidence in menstrual‐related migraine, pregnancy, lactation, and hormonal contraception: A narrative review. Headache: The Journal of Head and Face Pain, 66(10), 2230-2239. https://doi.org/10.1111/head.70195

Vancouver

Pejic J, Anandakumar J, Marks LA, Halker Singh RB, Ailani J. Anti‐calcitonin gene‐related peptide treatments in women's health: Gaps and clinical evidence in menstrual‐related migraine, pregnancy, lactation, and hormonal contraception: A narrative review. Headache: The Journal of Head and Face Pain. 2026;66(10):2230-2239. doi:10.1111/head.70195

BibTeX
@article{Pejic2026,
  author = {Pejic, Jelena and Anandakumar, Jeya and Marks, Lisa A and Halker Singh, Rashmi B and Ailani, Jessica},
  title = {Anti‐calcitonin gene‐related peptide treatments in women's health: Gaps and clinical evidence in menstrual‐related migraine, pregnancy, lactation, and hormonal contraception: A narrative review},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {10},
  pages = {2230--2239},
  doi = {10.1111/head.70195}
}
Start for free →